Liminatus Pharma — Valuation, Funding & Investors

Recent changes

Jun 23, 2026Jun 23, 2026Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public Pulse story
Jun 18, 2026Jun 18, 2026Raised $1.9M SEC EDGAR Form D

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Jun 18, 2026	funding round	$1.9M	—		SEC EDGAR Form D

Latest Pulse

Jun 23, 2026Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go PublicLiminatus Pharma, a clinical-stage biotech developing cancer immunotherapies, filed a Form S-1 with the SEC for an IPO. The filing is a sign of life in the long-dormant biotech IPO market, which has lagged the tech-led reopening.→

Coverage Timeline

newest first

Jun 23, 2026IPOCancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go PublicS-1 filed→

All Coverage

IPO· Jun 23, 2026

Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public

IPOS-1 filed

Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public

Liminatus Pharma, a clinical-stage biotech developing cancer immunotherapies, filed a Form S-1 with the SEC for an IPO. The filing is a sign of life in the long-dormant biotech IPO market, which has lagged the tech-led reopening.

Jun 23, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

SEC EDGAR Form Dprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction